In Section C, individuals will get ABBV-744 and oral navitoclax. In Section D, members will get ABBV-744 and ruxolitinib. Members will obtain treatment till ailment progression or perhaps the individuals are not able to tolerate the study drugs. 88 These preclinical studies deliver paradigms for long run clinical trials in https://isabbv-744effectiveforhem57913.snack-blog.com/31967513/top-guidelines-of-abbv-744-safety-and-side-effects